Inflammatory Bowel Diseases
Johnson & Johnson’s TREMFYA Receives FDA Approval for Ulcerative Colitis, Expanding Treatment Options
TREMFYA, guselkumab, FDA approval, ulcerative colitis, inflammatory bowel disease, Johnson & Johnson
Actionable Insights Powered by AI
TREMFYA, guselkumab, FDA approval, ulcerative colitis, inflammatory bowel disease, Johnson & Johnson